Literature DB >> 19235860

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.

Laurent Cotte1, Mary-Anne Trabaud, Jean-Claude Tardy, Corinne Brochier, René-Pierre Gilibert, Patrick Miailhes, Christian Trépo, Patrice André.   

Abstract

The current Agence Nationale de Recherche sur le SIDA (ANRS)/International AIDS Society (IAS) algorithm predicts resistance to etravirine for viruses harboring >/=3 mutations from a list of 13 reverse transcriptase (RT) mutations. Two weighted algorithms, best correlated with fold changes to etravirine, have been described recently. A retrospective virological analysis of a major French city HIV sequences database was undertaken to assess the proportion of etravirine resistant viruses according to these three algorithms and the correlations between them. Two thousand six hundred eighty RT sequences were analyzed, including 749 from naive patients and 926 from patients previously treated with non-nucleoside reverse transcriptase inhibitor (NNRTI). Combinations of mutations associated with etravirine resistance according to the three algorithms were found in 0%, 2.3%, and 3.6% of naive patients, and in 2.4%, 20.4%, and 19.3% of patients previously treated with NNRTIs. Concordance between the algorithms was weak (2 x 2 Kendall's tau: 0.787, 0.395, and 0.584). Most of the discordance was due to the differential weights attributed to Y181C/V, L100I, and K101P in the two weighted algorithms. It is concluded that the current ANRS/ IAS algorithm probably underestimates the proportion of viruses partially resistant to etravirine in NNRTI-experienced patients. Improvements in algorithms are needed to take into account the partial resistance associated with some mutation patterns, and should include either additional mutations to the current list and/or differential weights for specific mutations. Surveys of naive patients should be conducted to estimate the risk of primary resistance to etravirine in a minority of cases. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235860     DOI: 10.1002/jmv.21461

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru.

Authors:  Jaime Soria; Marta Bull; Caroline Mitchell; Alberto La Rosa; Sandra Dross; Kelli Kraft; Robert Coombs; Eduardo Ticona; Lisa Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

2.  Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Authors:  Almoustapha Issiaka Maïga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

3.  Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.

Authors:  Hongtao Xu; Yudong Quan; Bluma G Brenner; Tamara Bar-Magen; Maureen Oliveira; Susan M Schader; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

4.  Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.

Authors:  Shanmugam Saravanan; Bagavathi Kausalya; Selvamurthi Gomathi; Sathasivam Sivamalar; Balakrishnan Pachamuthu; Poongulali Selvamuthu; Amrose Pradeep; Solomon Sunil; Sarvode N Mothi; Davey M Smith; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-23       Impact factor: 1.723

5.  High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study.

Authors:  Christian Diamant Mossoro-Kpinde; Jean-Chrysostome Gody; Ralph-Sydney Mboumba Bouassa; Olivia Mbitikon; Mohammad-Ali Jenabian; Leman Robin; Mathieu Matta; Kamal Zeitouni; Jean De Dieu Longo; Cecilia Costiniuk; Gérard Grésenguet; Ndèye Coumba Touré Kane; Laurent Bélec
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

Authors:  Tamara Bar-Magen; Richard D Sloan; Verena H Faltenbacher; Daniel A Donahue; Björn D Kuhl; Maureen Oliveira; Hongtao Xu; Mark A Wainberg
Journal:  Retrovirology       Date:  2009-11-11       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.